Effects of nandrolone therapy on forearm bone mineral content in osteoporosis.
Forearm bone mineral content (BMC) was measured sequentially on and off anabolic steroid therapy in 52 postmenopausal women with osteoporosis. The steroid used was nandrolone decanoate in a dose of 50 mg every two weeks by intramuscular injection. In 16 of the patients nandrolone was given first (for 6.2 +/- 0.6 months) followed by a control period (6.1 +/- 1.0 months) and in 36 there was an initial control period (9.5 +/- 1.1 months) followed by nandrolone (for 5.8 +/- 0.4 months). Any other therapy was continued unchanged during both treatment and control periods. There was a significant rise in BMC on nandrolone (p less than 0.001) and a nonsignificant fall in BMC off nandrolone. The difference between the rates of change on and off nandrolone was highly significant (+53 vs. -7 mg/cm/year; p less than 0.001).
Need
A G
AG
Division of Clinical Chemistry, Institute of Medical and Veterinary Science, Adelaide, South Australia.
Horowitz
M
M
Morris
H A
HA
Walker
C J
CJ
Nordin
B E
BE
D000368:Aged; D045930:Anabolic Agents / Q000627:therapeutic use; D001862:Bone Resorption / Q000517:prevention & control; D001842:Bone and Bones / Q000032:analysis*; D002118:Calcium / Q000627:therapeutic use; D005260:Female; D005542:Forearm; D006801:Humans; D008593:Menopause; D008875:Middle Aged; D008903:Minerals / Q000032:analysis*; D009277:Nandrolone / Q000031:analogs & derivatives* / Q000494:pharmacology / Q000627:therapeutic use; D000077603:Nandrolone Decanoate; D010024:Osteoporosis / Q000517:prevention & control*
D045930:Anabolic Agents; D008903:Minerals; D009277:Nandrolone; D000077603:Nandrolone Decanoate; D002118:Calcium